SAB Biotherapeutics Inc. (SABS)

The total asset value of SAB Biotherapeutics Inc. (SABS) stood at $ 72 Mln as on 31-Mar-23

The share price of SAB Biotherapeutics Inc. (SABS) is $0.87 (NASDAQ) as of 06-Dec-2023 15:59 EST. SAB Biotherapeutics Inc. (SABS) has given a return of -18.7% in the last 1 years.

SAB Biotherapeutics Inc. (SABS) has a market capitalisation of $ 46 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of SAB Biotherapeutics Inc. (SABS) is 1.35 times as on 02-Jun-2023, a -0.47% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of SAB Biotherapeutics Inc. (SABS) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the SAB Biotherapeutics Inc. (SABS) and enter the required number of quantities and click on buy to purchase the shares of SAB Biotherapeutics Inc. (SABS).

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

The CEO & director of Mr. Samuel J. Reich. is SAB Biotherapeutics Inc. (SABS), and CFO & Sr. VP is Dr. Eddie Joe Sullivan Ph.D..

The promoters of SAB Biotherapeutics Inc. (SABS) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of SAB Biotherapeutics Inc. (SABS) was $-29 Mln.